National Cancer Institute (NCI) — CureCurrent

Published trials4,236

Recruiting shown60

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialNCT07388524 · lead sponsor · 2027-03-02

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain MetastasesNCT07619534 · lead sponsor · 2026-10-12

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseNCT07509034 · lead sponsor · 2026-10-12

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerNCT07137416 · lead sponsor · 2026-10-05

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation TherapyNCT07686380 · lead sponsor · 2026-10-01

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNCT07391774 · lead sponsor · 2026-08-10

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationNCT07012031 · lead sponsor · 2026-06-17

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)NCT07308886 · lead sponsor · 2026-04-08

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)NCT07067138 · lead sponsor · 2026-02-23

A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingNCT06066138 · lead sponsor · 2025-11-04

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionNCT06503146 · lead sponsor · 2025-09-09

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersNCT06479811 · lead sponsor · 2025-08-19

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionNCT06195306 · lead sponsor · 2025-07-28

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNCT06885697 · lead sponsor · 2025-07-08

The Vanguard Study: Testing a New Way to Screen for CancerNCT06995898 · lead sponsor · 2025-06-18

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerNCT06287775 · lead sponsor · 2025-04-08

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNCT06498635 · lead sponsor · 2025-04-01

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)NCT06052618 · lead sponsor · 2025-03-17

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerNCT05941520 · lead sponsor · 2024-10-10

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialNCT06184750 · lead sponsor · 2024-09-27

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO TrialNCT06022822 · lead sponsor · 2024-09-12

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844 · lead sponsor · 2024-07-19

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseNCT05907759 · lead sponsor · 2024-07-10

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)NCT06228066 · lead sponsor · 2024-06-13

Natural History Study of Kaposi SarcomaNCT06375122 · lead sponsor · 2024-05-15

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering TherapyNCT06096870 · lead sponsor · 2024-04-22

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung CancerNCT05777603 · lead sponsor · 2024-04-18

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate CancerNCT06161506 · lead sponsor · 2024-02-15

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaNCT05960773 · lead sponsor · 2024-01-31

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsNCT05691465 · lead sponsor · 2023-12-27

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · lead sponsor · 2023-11-27

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate TumorNCT05616650 · lead sponsor · 2023-10-19

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsNCT05372640 · lead sponsor · 2023-08-10

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasNCT05389423 · lead sponsor · 2023-06-27

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation TherapyNCT05361798 · lead sponsor · 2023-06-12

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerNCT05422794 · lead sponsor · 2023-05-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · lead sponsor · 2023-04-07

Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyLNCT05588128 · lead sponsor · 2023-03-21

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsNCT04665739 · lead sponsor · 2023-02-03

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...NCT05470491 · lead sponsor · 2023-01-26

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment InterruptionNCT05419024 · lead sponsor · 2023-01-09

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate CancerNCT04692675 · lead sponsor · 2022-11-18

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesNCT04923178 · lead sponsor · 2022-10-24

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical CarcinomaNCT05286814 · lead sponsor · 2022-10-24

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation TherapyNCT05155046 · lead sponsor · 2022-08-31

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerNCT05111561 · lead sponsor · 2022-08-02

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesNCT05327023 · lead sponsor · 2022-05-23

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVNCT04902443 · lead sponsor · 2021-12-10

Natural History of KSHV-Associated Multicentric Castleman s DiseaseNCT04968288 · lead sponsor · 2021-11-17

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaNCT04941274 · lead sponsor · 2021-09-29

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesNCT04959175 · lead sponsor · 2021-09-23

Precision-Based Genomics in Prostate CancerNCT04706663 · lead sponsor · 2021-09-14

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerNCT03606967 · lead sponsor · 2021-04-13

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate CancerNCT04633252 · lead sponsor · 2021-02-23

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · lead sponsor · 2020-12-28

Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsNCT04222413 · lead sponsor · 2020-10-27

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi SarcomaNCT04303117 · lead sponsor · 2020-07-13

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · lead sponsor · 2020-06-16

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVONCT03816345 · lead sponsor · 2019-07-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · lead sponsor · 2019-05-13

Sponsor roles

collaborator3,283

lead sponsor953

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.